Back to search results

Dominantly Inherited Alzheimer Network (DIAN) Study

This observational study, called DIAN, is looking for people aged 18 or older who have a parent with a known genetic mutation for early-onset Alzheimer's disease. The study aims to find early signs (biomarkers) of Alzheimer's in people who carry these mutations, even before symptoms appear. Researchers will collect blood, spinal fluid (lumbar puncture), and perform brain scans (MRI, FDG PET, PET amyloid imaging) to see how these markers change over time. They will also conduct interviews and cognitive tests. The goal is to understand how Alzheimer's develops in these families and to identify ways to predict its onset.

Study design
This is an observational study with a planned enrollment of 700 participants. It is not testing a specific drug or intervention.
What's involved
Participants will undergo blood draws, lumbar punctures, MRI, FDG PET, and PET amyloid imaging. They will also have clinical interviews and cognitive testing at variable follow-up assessments.
Compensation
Not stated in the trial record.
Follow-up
Follow-up assessments are variable, based on your age in relation to the age your affected parent started showing symptoms.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT00869817

Dominantly Inherited Alzheimer Network (DIAN)

Recruiting
Not specifiedAges 18+Observational
Washington University School of Medicine
~700 participants
Updated 2026-07-20 on ClinicalTrials.gov

At a glance

Recruiting sites
21 of 26 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Positive predictive power of a biomarker or group of biomarkers
Measured over Variable follow-up assessment based on age in relation to age at onset of affected parent.
+2 more outcomes measured

Conditions

Alzheimer's Disease

Explore related trials

Alzheimer's DiseaseAmyloid-Beta Precursor ProteinPresenilin-1Presenilin-2

Where it's being run

26 sites across 23 states
Japan3
Germany2
Florida1
Indiana1
Massachusetts1
Missouri1
New York1
Pennsylvania1

Study leadership

  • Eric McDade, DO · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine
  • Alisha Daniels, MD,MHA · STUDY_DIRECTOR · (314) 273-9057

Who to contact

Alisha Daniels, MD,MHA
(314) 273-9057
Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Written informed consent obtained from participant and collateral source prior to any study-related procedures.
Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD.
Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center.
Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study.
Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above.

Exclusion

Under age 18
Medical or psychiatric illness that would interfere in completing initial and follow-up visits
Requires nursing home level care
Has no one who can serve as a study informant

What this trial measures

  • Positive predictive power of a biomarker or group of biomarkersVariable follow-up assessment based on age in relation to age at onset of affected parent.
  • Biomarkers obtained by blood draw, lumbar puncture, MRI, FDG PET, PET amyloid imagingVariable follow-up assessment based on age in relation to age at onset of affected parent
  • Clinical markers also examined from clinical interview and cognitive testingVariable follow-up assessment based on age in relation to age at onset of affected parent